09:15 AM EDT, 09/16/2025 (MT Newswires) -- Lantern Pharma ( LTRN ) said Tuesday a phase 1a trial evaluating its drug LP-184 as a potential treatment for advanced relapsed or refractory solid tumors met all primary endpoints and showed a strong safety profile, favorable pharmacokinetics, and early signs of antitumor activity.

The company said no dose-limiting toxicities were reported in most cohorts, and side effects were mostly mild to moderate.

Lantern said it plans to advance LP-184 into phase 1b/2 trials targeting triple-negative breast cancer, non-small cell lung cancer, and bladder cancer.

Lantern Pharma ( LTRN ) shares were 7.4% higher in premarket trading.